Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Neuregulin 1 Antibodies:
anti-Human Neuregulin 1 Antibodies:
anti-Rat (Rattus) Neuregulin 1 Antibodies:
Go to our pre-filtered search.
Human Polyclonal Neuregulin 1 Primary Antibody for WB - ABIN516692
Nordqvist, Kårehed, Hambiliki, Wånggren, Stavreus-Evers, Akerud: The presence of histidine-rich glycoprotein in the female reproductive tract and in embryos. in Reproductive sciences (Thousand Oaks, Calif.) 2010
Show all 4 Pubmed References
Human Polyclonal Neuregulin 1 Primary Antibody for FACS, IHC (p) - ABIN390160
Ritch, Carroll, Sontheimer: Neuregulin-1 enhances motility and migration of human astrocytic glioma cells. in The Journal of biological chemistry 2003
Show all 4 Pubmed References
Study found that the expression level of the neuregulin-1 (NRG1) protein was increased in the medial prefrontal cortex of fear-conditioned mice and manipulation of NRG1 activity in the prelimbic cortex affected fear-conditioning behaviors.
The manipulation of NRG1/ErbB4 (show ERBB4 Antibodies) signaling in the present study revealed that NRG1/ErbB4 (show ERBB4 Antibodies) activity in the hippocampus is critical for learning and memory.
Nrg1-I intramuscular injection enhanced muscle reinnervation by collateral sprouting
These results collectively suggest that sustained activation of Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling in endothelial cells might be a cause of heart failure through suppressing neuregulin-ErbB (show EGFR Antibodies) signaling.
These results suggest that the neuropsin (show KLK8 Antibodies)-NRG1 signaling system has a role in pathological processes underlying temporal lobe epilepsy by regulating the activity of parvalbumin (show PVALB Antibodies)-expressing interneurons, and that neuropsin (show KLK8 Antibodies) regulates E/I balance and gamma oscillations through NRG1-ErbB4 (show ERBB4 Antibodies) signaling toward parvalbumin (show PVALB Antibodies)-expressing interneurons.
we show that the antifibrotic effect of neuregulin-1 is at least partially mediated through anti-inflammatory activity, linked to receptor tyrosine-protein kinase erbB-4 (show ERBB4 Antibodies) activation in macrophages
Results show that at ventral hippocampus-nucleus accumbens synapses, presynaptic type III Nrg1 bidirectional signaling controls the establishment of ventral hippocampus-nucleus accumbens glutamatergic synapses. Type III Nrg1 back-signaling contributes to functional synaptic vesicle clustering and neurotransmitter vesicle release.
Results demonstrate for the first time a link between a mutation of a schizophrenia risk gene, neuregulin 1 and altered neuronal resonance properties in sensory cortex.
findings reveal molecular, cellular, and circuit mechanisms of NRG1/ErbB4 (show ERBB4 Antibodies) in regulating the initiation of critical period visual cortical plasticity.
Data show that laminin alpha2beta1gamma1 (Lm211) can inhibit neuregulin 1 type III (Nrg1III) by limiting protein kinase A (PKA) activation, which is required to initiate myelination.
NRG1 and Gal-3 (show LGALS3 Antibodies) were significantly more elevated in cancer patients than in healthy controls.
The toxicity profile of lumretuzumab in combination with cetuximab and erlotinib was manageable, but only modest clinical activity was observed across tumor types. In the sqNSCLC cohort, there was no evidence of meaningful clinical benefit despite enriching for tumors with higher HRG mRNA expression levels.
Using time-resolved-fluorescence energy transfer (TR-FRET), we demonstrated that in the presence of recombinant NRG1, binding of 9F7-F11 (show F11 Antibodies) (a nonligand-competing anti-HER3 (show ERBB3 Antibodies) antibody) to HER3 (show ERBB3 Antibodies) is increased, whereas that of ligand-competing anti-HER3 (show ERBB3 Antibodies) antibodies is decreased.
Data suggest that SLC3A2 (show SLC3A2 Antibodies)-NRG1 should be considered a therapeutic target for patients with invasive mucinous adenocarcinoma of the lung (IMA).
we show that ErbB3 (show ERBB3 Antibodies) interacts with the ESCRT-0 subunit Hrs both in the presence and absence of heregulin. This indicates an ESCRT-mediated sorting of ErbB3 (show ERBB3 Antibodies) to late endosomes and lysosomes, and in line with this we show that impaired ESCRT function leads to an endosomal accumulation of ErbB3 (show ERBB3 Antibodies).
NRG1 genotype is associated with substance use.
Significant genetic risk for Hirschsprung disease (HSCR (show EDNRB Antibodies)) was imparted by rs2435357 and rs2506030 at RET (show RET Antibodies) and by rs12707682 at SEMA3 in a Chinese population. No evidence was found of a genetic association between HSCR (show EDNRB Antibodies) and either of the NRG1 SNPs rs7835688 and rs16879552, at either allele or genotype level.
High HRG1 expression is associated with breast cancer.
Results showed that heregulin-1ss mRNA was downregulated in 82 % of patients with hepatocellular carcinoma.
NRG1/ErbB2 (show ERBB2 Antibodies)/Src (show SRC Antibodies)/PTK2 (show PTK2 Antibodies) signaling pathway may be a novel regulator of keloid fibroblast migration.
Data suggest that epidermal growth factor receptor (show EGFR Antibodies) B [ErbB (show EGFR Antibodies)] isoforms and their ligands (epidermal growth factor (show EGF Antibodies) [EGF (show EGF Antibodies)], amphiregulin (show AREG Antibodies) [AREG (show AREG Antibodies)], and neuregulin-1 [NRG1]) are expressed in uteroplacental tissues in mid- and late-phases of pregnancy.
Cloning of a novel isoform of NRG1 (IgNRG1beta2) containing an immunoglobulin-like domain which is probably essential for efficient interaction with ErbB (show EGFR Antibodies) receptors.
The present research focused on morphological distribution of Nrg1 and its receptors, ErbB2 (show ERBB2 Antibodies) and ErbB4 (show ERBB4 Antibodies), in main gastrointestinal tissues of the non-human primate rhesus monkey.
we observed the activation of Notch (show NOTCH1 Antibodies) signaling in cardiomyocytes adjacent to those undergoing apical constriction, and we showed that this activation is positively regulated by Neuregulin signaling.
these results suggest that Nrg1 is not the primary effector of trabeculation and/or that other EGF (show EGF Antibodies)-like ligand(s) activates the ErbB2 (show ERBB2 Antibodies)/ErbB4 (show ERBB4 Antibodies) pathway, either through functioning as the primary ligand or acting in a redundant manner. Overall, our work provides an example of cross-species differences in EGF (show EGF Antibodies) family member requirements for an evolutionary conserved process.
Notch1 (show NOTCH1 Antibodies) activation induces expression of ephrin b2a (efnb2a (show EFNB2 Antibodies)) and neuregulin 1 (nrg1) in the endocardium to promote trabeculation and forced Notch (show NOTCH1 Antibodies) activation in the absence of cardiac contraction rescues efnb2a (show EFNB2 Antibodies) and nrg1 expression
These findings identify Nrg1 as a potent, induced mitogen for the endogenous adult heart regeneration program.
These results demonstrate that Nrg1 type III is an essential signal that controls Schwann cell migration to ensure that these glia are present in the correct numbers and positions in developing nerves.
ErbB3 (show ERBB3 Antibodies) signaling is required for normal migration of trunk, but not cranial, neural crest cells
Disc1 (show DISC1 Antibodies) and nrg1 function in controlling development of oligodendrocytes and neurones from olig2 (show OLIG2 Antibodies)-expressing precursor cells.
NRG1 and PI3K functionally interact with ErbB2 (show ERBB2 Antibodies) and ErbB3 (show ERBB3 Antibodies) during regeneration
The protein encoded by this gene was originally identified as a 44-kD glycoprotein that interacts with the NEU/ERBB2 receptor tyrosine kinase to increase its phosphorylation on tyrosine residues. This protein is a signaling protein that mediates cell-cell interactions and plays critical roles in the growth and development of multiple organ systems. It is known that an extraordinary variety of different isoforms are produced from this gene through alternative promoter usage and splicing. These isoforms are tissue-specifically expressed and differ significantly in their structure, and thereby these isoforms are classified into types I, II, III, IV, V and VI. The gene dysregulation has been linked to diseases such as cancer, schizophrenia and bipolar disorder (BPD).
, pro-neuregulin-1, membrane-bound isoform
, type I neuregulin 1
, type III neuregulin 1
, neuregulin 1
, glial growth factor
, heregulin, alpha (45kD, ERBB2 p185-activator)
, neu differentiation factor
, neuregulin 1 type IV beta 1a
, neuregulin 1 type IV beta 3
, sensory and motor neuron derived factor
, neuregulin 1 type III beta 3
, membrane-bound isoform
, neuregulin 1 alpha isoform